- Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in
China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in 46 COVID-19 patients with 300 mg BID, 600 mg BID and 800 mg BID daily dosing for 7.5 days. - Overall, STI-1558 was well-tolerated at all doses tested, with most subjects in both the SAD and MAD portions of the study reporting no adverse events (AEs). There was no dose limiting toxicity during the study. There were no severe or serious AEs, no premature discontinuations of STI-1558 due to an AE, and no deaths. Most AEs were mild, unrelated and required no medical treatment.
- In the MAD portion of the study (n=41 evaluable), COVID-19 patients (n=29) treated with STI-1558 compared to placebo (n=12) were found to have significant viral RNA load reductions on Days 2, 4 and 6 post treatment. At the recommended dose of 600 mg BID, a significant viral load reduction was seen on Day 2 post-treatment (1.5 log lower than placebo, p=0.036), which indicates strong and early antiviral activity of STI-1558 in COVID-19 patients.
- The Pharmacokinetics (PK) profile in this trial was very similar to the profile seen in the completed Australian Phase 1 trial, potentially indicating that there are no ethnic differences in STI-1558 PK. In the China MAD portion of the study, the PK profile in patients was also similar to the healthy volunteers in the Australian Phase 1 trial, with the trough concentrations (Ctrough) 265 (300 mg BID), 431 (600 mg BID) and 518 (800 mg BID) ng/mL values significantly higher than the EC90 value in the cellular antiviral assays. These data further confirm that adequate blood levels are achieved in COVID-19 patients without the need for Ritonavir, a CYP3A4 potent inhibitor, as a booster.
- After communication with the Chinese authorities, a Phase 3 protocol in 1200 COVID-19 patients has been submitted to the
National Medical Products Administration of China (NMPA). The Phase 3 trial will be commenced soon inChina together with a plannedU.S. Phase 2 trial and a planned Mexico Phase 2/3 trial.
This Phase 1b safety, PK and efficacy study in healthy volunteers and COVID patients was conducted in China. The study (MPR-COV-101CN) is entitled: “A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Single and Multiple Oral Doses of STI-1558 in
The topline safety, PK and efficacy data from the SAD and MAD portions of the study are now available. Overall, STI-1558 was well-tolerated at these doses, with most subjects in both the SAD and MAD portions of the study reporting no AEs. There was no dose limiting toxicity during the study. There were no severe or serious AEs, no premature discontinuations of STI-1558 due to an AE, and no deaths. Most AEs were mild, transient, unrelated and required no medical treatment.
A total of 12 subjects reported an AE in the SAD portion of the study, with one AE of elevated blood thyroid-stimulating hormone (TSH) deemed related to STI-1558 in the 2000 mg cohort. No headaches were seen in this study. In the MAD portion of the study in COVID-19 patients, 20 subjects from a total of 46 subjects reported AEs, with only four subjects experiencing STI-1558-related events. These four AEs included two subjects with mild or moderate liver enzyme elevation (ALT/AST) without bilirubin elevation in the 300 BID and 800 BID cohorts, one subject with mild hyperuricemia in the 600 mg BID cohort and one subject with mild rash in the 800 mg BID cohort.
Antiviral activity was evaluated in the MAD portion of the study in participants infected with SARS-CoV2 (300 mg BID, 600 mg BID and 800 mg BID daily for 7.5 days). The viral RNA load in participants infected with SARS-CoV2 was measured by quantitative PCR. The viral RNA load (log10 copies/ml) was significantly reduced in COVID-19 patients (n=29) treated with STI-1558 on Days 2, 4 and 6 post-treatment in comparison with placebo, indicating the strong antiviral activity of STI-1558 in COVID-19 patients. Notably the significant reduction of viral RNA (Log10 copies/ml) can be seen as early as day 2 after being treated with STI-1558 at the likely therapeutic dose of 600 mg BID (1.5 log lower than placebo, p=0.036). These data demonstrate early antiviral activity of STI-1558 in COVID-19 patients.
The PK profiles in the
Based on the safety and PK profiles and significant antiviral efficacy in COVID-19 patients, a 600 mg twice-daily dose for 5 days has been selected as a recommended dose for Phase 3 studies for the standalone treatment of COVID-19.
After communication with the regulatory agency, a Phase 3 protocol was submitted to China NMPA. The Phase 3 trial (MPR-COV-301CN) is entitled: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of STI-1558 for Treatment of Mild and Moderate Symptomatic Adults Infected with SARS-CoV-2”. Once cleared by NMPA, the study, which plans to enroll 1200 COVID-19 patients, will be subsequently commenced.
“We are excited to see the similarities of PK in the
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVISHIELD™ and COVIDROPS™, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations
Contact:
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are trademarks of
SEMDEXA™ (SP-102) is a trademark of
ZTlido® is a registered trademark owned by
All other trademarks are the property of their respective owners.
©2022
![](https://ml.globenewswire.com/media/Yjg0MGQwZmEtYzNjMC00ZjVlLTkyMDYtNDIyYWMzMzk0YTViLTEwNjE0MTU=/tiny/Sorrento-Therapeutics-Inc-.png)
2023 GlobeNewswire, Inc., source